Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 15718586

The road ahead.

Ilias Iakovidis·Petra Wilson·Jean Claude Healy
View original source ↗Export metadata ↓

Abstract

The recent events dedicated to eHealth, such as eHealth 2003 and eHealth 2004 Ministerial conferences and exhibition, demonstrated clearly that a critical mass of users is being created who already use eHealth services and applications. Citizens, patients and health professionals are experiencing growing benefits from the use of eHealth applications which can increase citizen information, increase patient empowerment, speed up delivery, and reduce medical risks. Yet despite their availability and proven benefits, eHealth systems and services are not yet widely used in real-life medical or health situations. In many places, development is still at a pilot phase, often financed through research grants.

Explore related subjects

Congresses as TopicDiffusion of InnovationEuropean UnionForecastingHumansLeadershipMedical Informatics ApplicationsTechnology Assessment, BiomedicalJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ilias Iakovidis, Petra Wilson, Jean Claude Healy. 2004. The road ahead.. https://pubmed.ncbi.nlm.nih.gov/15718586/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

On-demand therapy for gastroesophageal reflux disease.

The following pages summarize the proceedings of a symposium held in May 2006 on the emerging role of on-demand therapy for gastroesophageal reflux disease (GERD). Medical therapy for GERD has undergone significant change in recent years with the advent of effective, but expensive, antisecretory agents. On-demand (patient-driven) therapy is attractive to payers and patients, because it appears to be both cost-effective and convenient. Many individuals appear to accept occasional symptomatic breakthrough in exchange for personal control of their disease. On-demand therapy should be distinguished from intermittent therapy, which is either patient- or physician-driven, but which requires intermittent episodes of continuous therapy followed by discontinuation until symptoms recur. Proton pump inhibitors appear to be effective on-demand agents despite theoretical pharmacodynamic limitations for this class of drug. The available data support the use of on-demand therapy for GERD in uninvestigated reflux disease, nonerosive reflux disease, and possibly mild esophagitis as well. On-demand therapy should not be considered for patients with severe esophagitis.

Congresses as Topic↗